Evidence map›Paper›PMID 35268072›Full record

ArticleNutrients2022

(-)-Epicatechin Improves Vasoreactivity and Mitochondrial Respiration in Thermoneutral-Housed Wistar Rat Vasculature.

Ji Hye Chun, Melissa M Henckel, Leslie A Knaub, Sara E Hull, Greg B Pott, Lori A Walker, Jane E-B Reusch, Amy C Keller

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Hypolipidemic effect and mechanism of Hedan tablet based on network pharmacology.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ji Hye ChunMicrotek, Inc., San Diego, CA 92127, USA.
Melissa M HenckelRocky Mountain Regional VA Medical Center, Aurora, CO 80045, USA.ORCID 0000-0003-0170-6091
Leslie A KnaubRocky Mountain Regional VA Medical Center, Aurora, CO 80045, USA.
Sara E HullRocky Mountain Regional VA Medical Center, Aurora, CO 80045, USA.
Greg B PottRocky Mountain Regional VA Medical Center, Aurora, CO 80045, USA.
Lori A WalkerDivision of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Jane E-B ReuschRocky Mountain Regional VA Medical Center, Aurora, CO 80045, USA.
Amy C KellerRocky Mountain Regional VA Medical Center, Aurora, CO 80045, USA.
University of Colorado Anschutz Medical Campus · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI DANIEL Holland BESSESEN · 1995 to 2026
$32.6M
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI PETER J DEMPSEY · 2020 to 2026
$10.8M
Role of Microvascular insulin resistance and cardiorespiratory fitness in diabetesR01DK124344 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI ZHENQI LIU, JUDITH G. REGENSTEINER · 2021 to 2026
$3.5M
Repair of Vascular Contractility and Mitochondrial Function by NOS RecouplingIK2BX003185 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI KELLER, AMY CELESTE · 2017 to 2022
–
BLRD VA IK2 BX003185Denver Research Institute N/AFamily Center for Women's Health Research at the University of Colorado Anschutz Medical Campus Junior Faculty Research Development GrantNIDDK NIH HHS P30 DK048520NIH HHS DK124344-01A1NIH HHS P30-DK116073NIH HHS UL1 RR025780VA BX002046VA BX003185
6 · The paper itself

Abstract

Cardiovascular disease (CVD) is a global health concern. Vascular dysfunction is an aspect of CVD, and novel treatments targeting vascular physiology are necessary. In the endothelium, eNOS regulates vasodilation and mitochondrial function; both are disrupted in CVD. (−)-Epicatechin, a botanical compound known for its vasodilatory, eNOS, and mitochondrial-stimulating properties, is a potential therapy in those with CVD. We hypothesized that (−)-epicatechin would support eNOS activity and mitochondrial respiration, leading to improved vasoreactivity in a thermoneutral-derived rat model of vascular dysfunction. We housed Wistar rats at room temperature or in thermoneutral conditions for a total of 16 week and treated them with 1mg/kg body weight (−)-epicatechin for 15 day. Vasoreactivity, eNOS activity, and mitochondrial respiration were measured, in addition to the protein expression of upstream cellular signaling molecules including AMPK and CaMKII. We observed a significant improvement of vasodilation in those housed in thermoneutrality and treated with (−)-epicatechin (p < 0.05), as well as dampened mitochondrial respiration (p < 0.05). AMPK and CaMKIIα and β expression were lessened with (−)-epicatechin treatment in those housed at thermoneutrality (p < 0.05). The opposite was observed with animals housed at room temperature supplemented with (−)-epicatechin. These data illustrate a context-dependent vascular response to (−)-epicatechin, a candidate for CVD therapeutic development.

Indexed as

CatechinAnimalsMitochondriaRatsRats, WistarRespirationSignal TransductionCatechincardiovascular diseaseeNOSvascular

Identifiers

PMID35268072
PMCPMC8912787
OpenAlexW4221114855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.